检查点抑制剂是否会损害癌症患者的免疫力，增加感染 COVID-19 的脆弱性？
Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?
机构信息
Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
出版信息
Immunotherapy. 2020 Apr;12(6):351-354. doi: 10.2217/imt-2020-0077. Epub 2020 Apr 14.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.
摘要
世界卫生组织宣布严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）为大流行病毒，在短短几个月内导致数千人死亡。癌症患者由于抗癌治疗引起的获得性免疫缺陷而成为弱势群体。免疫检查点抑制剂极大地影响了多种恶性肿瘤的预后，显著改善了生存结果，并具有不同且可耐受的毒性特征。在本文中，我们评估了在冠状病毒大流行期间癌症患者使用 ICI 的安全性，以指导这些高效药物的使用。
相似文献
1
Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?检查点抑制剂是否会损害癌症患者的免疫力，增加感染 COVID-19 的脆弱性？
Immunotherapy. 2020 Apr;12(6):351-354. doi: 10.2217/imt-2020-0077. Epub 2020 Apr 14.
2
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.COVID-19 对癌症免疫治疗相关风湿并发症患者的影响：一项注册调查研究结果。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001550.
3
COVID-19 associated viral myocarditis: does it exist?新型冠状病毒肺炎相关的病毒性心肌炎：它存在吗？
Monaldi Arch Chest Dis. 2020 Sep 9;90(4). doi: 10.4081/monaldi.2020.1382.
4
SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?严重急性呼吸综合征冠状病毒2感染与高危非肌层浸润性膀胱癌：有哪些共同特征？
Urol Int. 2020;104(7-8):510-522. doi: 10.1159/000509065. Epub 2020 Jun 9.
5
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.免疫检查点抑制剂对病毒感染和新冠肺炎的潜在保护及治疗作用。
Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29.
6
Could reperfusion pulmonary oedema explain worsening progress in COVID-19 pneumonia?再灌注性肺水肿能解释新冠病毒肺炎病情的恶化进展吗？
Emerg Med J. 2020 Nov;37(11):705-706. doi: 10.1136/emermed-2020-210085. Epub 2020 Sep 28.
7
COVID-19 and immune checkpoint inhibitors: initial considerations.COVID-19 与免疫检查点抑制剂：初步考虑。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000933.
8
ICI Impact on COVID-19 Severity Modest at Best.ICI 对 COVID-19 严重程度的影响充其量只是适度的。
Cancer Discov. 2020 Oct;10(10):1432-1433. doi: 10.1158/2159-8290.CD-NB2020-079. Epub 2020 Aug 19.
9
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.COVID-19 与肾脏疾病：肾癌中的分子决定因素和临床意义。
Eur Urol Focus. 2020 Sep 15;6(5):1086-1096. doi: 10.1016/j.euf.2020.06.002. Epub 2020 Jun 9.
10
Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China.中国武汉 4 例新型冠状病毒感染的癌症患者的临床特征。
Infect Dis Poverty. 2020 Jul 2;9(1):82. doi: 10.1186/s40249-020-00707-1.
引用本文的文献
1
Evaluating the impact of COVID-19 on cancer care: a comprehensive analysis of treatment modifications, risk factors, and patient outcomes.评估2019冠状病毒病对癌症护理的影响：对治疗调整、风险因素和患者结局的综合分析。
BMC Infect Dis. 2025 Jun 2;25(1):779. doi: 10.1186/s12879-025-11172-2.
2
Effects of the COVID-19 pandemic on care of melanoma patients in Berlin, Germany: the Mela-COVID survey.COVID-19 大流行对德国柏林黑色素瘤患者护理的影响：Mela-COVID 调查。
Eur J Dermatol. 2022 Jul 1;31(4):521-529. doi: 10.1684/ejd.2021.4098. Epub 2021 Aug 26.
3
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).黑色素瘤视角：黑色素瘤桥接会议报告（2021 年 12 月 2 日-4 日，意大利）。
J Transl Med. 2022 Sep 4;20(1):391. doi: 10.1186/s12967-022-03592-4.
4
Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.需要全面调整的结果数据来评估免疫检查点抑制剂在 COVID-19 癌症患者中的影响：系统评价和荟萃分析的结果。
Rev Med Virol. 2022 Sep;32(5):e2352. doi: 10.1002/rmv.2352. Epub 2022 Apr 13.
5
Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence.免疫疗法与纳米疗法对感染SARS-CoV-2的癌症患者的协同作用及人工智能的应用
Cancers (Basel). 2022 Jan 2;14(1):213. doi: 10.3390/cancers14010213.
6
Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.先前接触免疫检查点抑制剂治疗是否会影响癌症患者 COVID-19 的发病率和死亡率：系统评价和荟萃分析。
Int Immunopharmacol. 2021 Dec;101(Pt A):108242. doi: 10.1016/j.intimp.2021.108242. Epub 2021 Oct 11.
7
Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.与免疫检查点抑制剂使用相关的肺部毒性：癌症支持治疗多国协会中性粒细胞减少、感染与骨髓抑制研究组免疫肿瘤学亚组的最新进展
Front Pharmacol. 2021 Oct 5;12:743582. doi: 10.3389/fphar.2021.743582. eCollection 2021.
8
Immunological Approaches to the Treatment of New Coronavirus Infection (Review).免疫治疗新型冠状病毒感染的方法（综述）。
Sovrem Tekhnologii Med. 2021;13(3):81-99. doi: 10.17691/stm2021.13.3.09. Epub 2021 Jun 28.
9
ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO).意大利心脏病学协会立场文件：新冠疫情时代的心衰与癌症共病（CO与CO）
Eur Heart J Suppl. 2021 Aug 26;23(Suppl C):C128-C153. doi: 10.1093/eurheartj/suab067. eCollection 2021 Aug.
10
The Impact of () Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review.合并症患者中（）表达水平对COVID-19严重程度的影响：一项综述。 （注：原文括号处内容缺失）
Microorganisms. 2021 Aug 9;9(8):1692. doi: 10.3390/microorganisms9081692.
本文引用的文献
1
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.意大利新冠肺炎死亡患者的病死率及特征
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
2
COVID-19 and Italy: what next?COVID-19 和意大利：下一步如何？
Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.
3
Risk of COVID-19 for patients with cancer.癌症患者感染新型冠状病毒肺炎的风险。
Lancet Oncol. 2020 Apr;21(4):e180. doi: 10.1016/S1470-2045(20)30150-9. Epub 2020 Mar 3.
4
COVID-19-New Insights on a Rapidly Changing Epidemic.《2019冠状病毒病——快速演变疫情的新见解》
JAMA. 2020 Apr 14;323(14):1339-1340. doi: 10.1001/jama.2020.3072.
5
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
6
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
7
Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗后的免疫相关性中性粒细胞减少症。
J Immunother. 2020 Feb/Mar;43(2):67-74. doi: 10.1097/CJI.0000000000000293.
8
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.免疫检查点抑制剂的不良反应：流行病学、管理和监测。
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0.
9
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.与抗程序性死亡 1 相关的带状疱疹后肉芽肿性皮肤病。
Immunotherapy. 2019 May;11(7):591-598. doi: 10.2217/imt-2018-0169.
10
Optimal Management of Neutropenic Fever in Patients With Cancer.癌症患者中性粒细胞减少性发热的最佳管理。
J Oncol Pract. 2019 Jan;15(1):19-24. doi: 10.1200/JOP.18.00269.
Zotero 插件